Gimsilumab
- Generic Name
- Gimsilumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1648796-29-5
- Unique Ingredient Identifier
- 8961SFA7R3
- Background
Gimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Kinevant Sciences GmbH
- Target Recruit Count
- 227
- Registration Number
- NCT04351243
- Locations
- 🇺🇸
Banner University Medical Center, Tucson, Arizona, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath